Impact of the high baseline anti-A/B antibody titer on the clinical outcomes in ABO-incompatible living donor liver transplantation

Boram Lee¹, Jai Young Cho¹, Suk Kyun Hong², YoungRok Choi², Hae Won Lee¹, Namjoon Yi², Kwang-Woong Lee², Kyung-Suk Suh², Ho-Seong Han¹

¹Department of Surgery-Hepatobiliary, Seoul National University Bundang Hospital, Seongnam, Korea

²Department of Surgery-Transplantation, Seoul National University Hospital, Seoul, Korea

Background: Recently, advances in desensitization protocol have made ABO-incompatible (ABOi) living donor liver transplantation (LDLT) feasible option in the era of organ shortage. Although, multiple sessions of plasmapheresis can successfully reduce preformed anti-A/B titer prior to transplantation, the clinical significance of baseline anti-A/B antibody titers remains uncertain. The aim of this study is to investigate the clinical outcomes of ABOi LDLT in patients with a high baseline anti-A/B antibody titer.

Methods: A total of 50 patients who received ABOi LDLT from 2010 to 2020 at two tertiary hospitals were evaluated retrospectively. Two centers used a protocol composed of rituximab, plasmapheresis, and/or splenectomy. The patients were classified according to baseline anti-A/B titer ($<1:256$, $n=88$ or $\geq 1:256$, $n=62$) and compared the clinical outcomes among these groups. Graft survival rates were calculated using the Kaplan-Meier methods according to the groups.

Results: In the high baseline titer group, the number of plasmaphereses required to reach the target titer (1:16) was significantly higher (4.4 ± 2.2 sessions) than in the low baseline titer group (1.9 ± 1.2 sessions, $P < 0.001$). Fourteen patients (16.4%) in high baseline titer group and seven patients (9.2%) in low baseline titer group experienced postoperative titer rebound to $\geq 1:32$, ($P = 0.014$). The occurrence of both cellular rejection and antibody-mediated rejection did not show a significant difference ($P = 0.251$ and $P = 0.147$, respectively). The 1-, 3-, and 5-year graft survival was not different among groups (high titer vs. low titer; 94.2%, 83.3%, and 59.0% vs. 92.1%, 86.3%, and 79.5%; $P = 0.326$). In multivariate analysis showed that high baseline anti-A/B titer and postoperative rebound titer did not adversely affect clinical outcomes after ABOi LDLT.

Conclusions: Although, the patients with high baseline anti-A/B titer showed the higher tendency of postoperative antibody rebound, the baseline and rebound anti-A/B titer may not be as important factors for clinical outcomes of ABOi LDLT if appropriate desensitization is performed.

Corresponding author: Jai Young Cho

E-mail: jychogs@gmail.com

© The Korean Society for Transplantation

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.